

# Residency Fellowship Forum Series: The Curbside Consult A Webinar Series for Anesthesiology Residents and Fellows

## **Overview:**

Pacira BioSciences, Inc., is very pleased to offer a series of four webinars focused on topics that fellows and residents may not have had exposure to in their training. This series will include thought-provoking and interactive discussions around "other" nuances to being an attending physician that will be useful both early in a career in anesthesiology and beyond.

# January 12, 2021 7:00 pm Eastern Webinar #1: "Where am I going?" Signing My First Contract: Hospital Employment vs Large Group Practice vs Academia

## Click here to register!



## Moderator: Jeffrey Gonzales, MD

Jeffrey Gonzales, MD, is currently a staff Anesthesiologist at Parker Adventist Hospital and the Chair of Acute Pain at Parker Adventist Hospital, Parker CO. He completed his Regional Anesthesia/Acute Pain Fellowship at Duke University, Durham, NC.



## Guest Speaker: Richard S. Teames, MD, BSN

Richard S. Teames, MD, BSN, earned his bachelors of science in nursing at the University of Utah. Dr Teames graduated summa cum laude from St. George's School of Medicine and trained in Anesthesiology at University of Texas, Houston. During residency Dr Teames joined the United States Army Reserve Medical Corp program. Dr Teames is the Director of Regional Anesthesia and National Clinical Director of Regional Anesthesia for Envision Physician Services.

Be sure to look for invitations to the next installments in this series!

# **FUTURE SERIES**

Webinar #2: "What to do when I get there?"

The value of acute pain management: the battles of starting a regional block program, who needs to be involved and how to get it done? How to get senior partners and surgeons on board?

Moderator: Jeffrey Gonzales, MD Guest Speaker: Richard Teames, MD, BSN

#### Webinar #3: "What I haven't learned?"

What is a stakeholder? The business and art of successfully engaging and negotiating with the hospital administration, Pharmacy and Therapeutic Committee (P&T) and Value Analysis Committee (VAT).

## Webinar #4: "What's next?"

Hot topics my fellowship didn't teach me.

## Questions? Contact the Medical Innovation and Education team at either number below: Christa D'Agnese: 404-906-3550 or Danielle Resseguet: 504-939-9957

We hope to see you at one or more of these informative events!

Sincerely,

Pacira BioSciences, Inc. www.Pacira.com www.EXPAREL.com

Please see full Prescribing Information here and Important Safety Information below.

## Indication

EXPAREL<sup>®</sup> (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

#### **Important Safety Information**

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

### Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra- articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

## Warnings and Precautions for Bupivacaine-Containing Products

**Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

**Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

**Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

**Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

**Methemoglobinemia:** Cases of methemoglobinemia have been reported with local anesthetic use.

For more information, please visit <u>www.EXPAREL.com</u> or call 1-855-793-9727.



©2020 Pacira BioSciences, Inc. Parsippany, NJ 07054 PP-EX-US-6318 11/20

If you wish to unsubscribe from receiving emails such as this, click here.